Work

Treatment of an Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Harboring STAT3::JAK2 With Jakafi (Ruxolitinib) With Significant Clinical Improvements

Year: 2025

Type: article

Abstract: ABSTRACT Introduction Indolent T‐cell lymphoma of the gastrointestinal tract (ITCL‐GI) is a rare primary T‐cell lymphoma from the gastrointestinal (GI) tract, there has been no documented successful treatment at the present time. Results A CD4(+)/CD8(−) ITCL‐GI with STAT3::JAK2 fusion was treated with Jakafi (Ruxolitinib), which resulted in significant clinical improvements. Conclusion Next generation sequencing is highly recommended for any new diagnosis of CD4(+)/CD8(−) ITCL‐GI in order to detect if STAT3::JAK2 can be found in order to treat the patient with JAK2 inhibitor such as Jakafi (Ruxolitinib). Clinical trial registration The authors have confirmed clinical trial registration is not needed for this submission.

Source: eJHaem

DOI: 10.1002/jha2.70047

Authors: Xi Cao, Carolyn Mulroney, Huan‐You Wang

Institution: University of California San Diego

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,860